Survival gains needed to offset persistent adverse treatment effects in localised prostate cancer

Nature Publishing Group
Publication Type:
Journal Article
British Journal Of Cancer, 2012, 106 (4), pp. 638 - 645
Issue Date:
Full metadata record
Files in This Item:
Filename Description SizeFormat
2010006514OK.pdf16.69 MBAdobe PDF
Men diagnosed with localised prostate cancer (LPC) face difficult choices between treatment options that can cause persistent problems with sexual, urinary and bowel function. Controlled trial evidence about the survival benefits of the full range of treatment alternatives is limited, and patients' views on the survival gains that might justify these problems have not been quantified. A discrete choice experiment (DCE) was administered in a random subsample (n = 357, stratified by treatment) of a population-based sample (n = 1381) of men, recurrence-free 3 years after diagnosis of LPC, and 65 age-matched controls (without prostate cancer). Survival gains needed to justify persistent problems were estimated by substituting side effect and survival parameters from the DCE into an equation for compensating variation (adapted from welfare economics). Median (2.5, 97.5 centiles) survival benefits needed to justify severe erectile dysfunction and severe loss of libido were 4.0 (3.4, 4.6) and 5.0 (4.9, 5.2) months. These problems were common, particularly after androgen deprivation therapy (ADT): 40 and 41% overall (n = 1381) and 88 and 78% in the ADT group (n = 33). Urinary leakage (most prevalent after radical prostatectomy (n - 839, mild 41%, severe 18%)) needed 4.2 (4.1, 4.3) and 27.7 (26.9, 28.5) months survival benefit, respectively. Mild bowel problems (most prevalent (30%) after external beam radiotherapy (n = 106)) needed 6.2 (6.1, 6.4) months survival benefit.
Please use this identifier to cite or link to this item: